TARA-002膀胱内给药与研究者选择的膀胱内化疗在BCG初治高危非肌层浸润性膀胱癌患者中的疗效和安全性比较 (ADVANCED-3)
一项3期随机研究,旨在评估膀胱内注射TARA-002对比研究者选择的膀胱内化疗在BCG未治疗的高级别非肌层浸润性膀胱癌参与者中的疗效和安全性
The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.
The main questions it aims to answer are:
- Can the study drug help participants with this type of cancer?
- Is the study drug safe?
- What are the side effects of the study drug?
Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Chief R&D Officer
- 电话号码:16468440337
- 邮箱:clinicaltrials@protaratx.com
学习地点
-
-
-
Ivano-Frankivsk、乌克兰、76018
- 招聘中
- Arenia - Ivano-Frankivsk
-
接触:
- Use Central Contact
-
Kapitanivka、乌克兰、08111
- 招聘中
- Arensia Kapitanivka - PPDS
-
接触:
- Use Central Contact
-
-
-
-
Arizona
-
Queen Creek、Arizona、美国、85140
- 招聘中
- East Valley Urology Center of Arizona
-
接触:
- Use Central Contact
-
-
Arkansas
-
Little Rock、Arkansas、美国、72211
- 招聘中
- Arkansas Urology
-
接触:
- Use Central Contact
-
-
California
-
Bakersfield、California、美国、93301
- 招聘中
- Michael Oefelein Clinical Trials
-
-
Georgia
-
Atlanta、Georgia、美国、30319
- 招聘中
- Urology of Greater Atlanta - Sandy Springs
-
接触:
- Use Central Contact
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Renown Regional Medical Center
-
接触:
- Use Central Contact
-
-
South Carolina
-
Myrtle Beach、South Carolina、美国、29572
- 招聘中
- START - Carolinas
-
接触:
- Use Central Contact
-
-
Texas
-
Arlington、Texas、美国、76017
- 招聘中
- Urology Partners of North Texas
-
接触:
- Use Central Contact
-
Austin、Texas、美国、78745
- 招聘中
- Urology Austin, LLC
-
接触:
- Use Central Contact
-
Houston、Texas、美国、77027
- 招聘中
- Houston Metro Urology
-
接触:
- Use Central Contact
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female participants 18 years of age or older at the time of signing informed consent
- Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry
- Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease
- Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis, or participants who received ≤2 doses of BCG within the 24 months prior to the most recent CIS diagnosis
Exclusion Criteria:
- Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory
- Central confirmed variant histology
- Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment
- Nodal and metastatic disease are excluded if they existed at any time (whether present or in the past)
- Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history
For more information on eligibility criteria, please contact the Sponsor.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:TARA-002(A组)
|
Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of TARA-002. Participants who undergo reinduction and are confirmed to have a CR at Week 24 will enter the maintenance regimen treatment period and will receive 3 weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. |
|
有源比较器:研究者选择的膀胱内化疗
|
Participants will receive 6 weekly instillations of Investigator's choice of intravesical chemotherapy. Participants confirmed to have a CR at Week 12 will enter the maintenance regimen treatment period and will receive one intravesical instillation of Investigator's choice of intravesical chemotherapy every 1 month up to Month 25. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of high-grade complete response
大体时间:Month 6
|
Incidence of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) |
Month 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Duration of high-grade complete response
大体时间:Up to Month 60
|
Duration of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Treatment emergent adverse events
大体时间:Up to Month 60
|
Incidence and severity of treatment emergent adverse events (TEAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Treatment emergent serious adverse events
大体时间:Up to Month 60
|
Incidence and severity of treatment emergent serious adverse events (TESAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
High-grade complete response rate
大体时间:At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60
|
High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) |
At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60
|
|
High-grade complete response rate (CIS only)
大体时间:Month 6
|
High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) in sub-group of participants with CIS only |
Month 6
|
|
Event-free survival
大体时间:Up to Month 60
|
Event-free survival (EFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Recurrence-free survival
大体时间:Up to Month 60
|
Recurrence-free survival (RFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Progression-free survival
大体时间:Up to Month 60
|
Progression-free survival (PFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Disease-specific progression-free survival
大体时间:Up ro Month 60
|
Disease-specific progression-free survival (DSPFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up ro Month 60
|
|
Overall survival
大体时间:Up to Month 60
|
Overall survival (OS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Disease-specific survival
大体时间:Up to Month 60
|
Disease-specific survival (DSS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to cystectomy
大体时间:Up to Month 60
|
Time to cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to recurrence delayed cystectomy
大体时间:Up to Month 60
|
Time to recurrence delayed cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to progression
大体时间:Up to Month 60
|
Time to progression of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to disease worsening
大体时间:Up to Month 60
|
Time to disease worsening of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TARA-002-301
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.